Last reviewed · How we verify
NCT07384039: MPN-Exercise
Exercise Training in Patients With Myeloproliferative Neoplasms
NA trial testing Exercise Training in Myeloproliferative Neoplasms (MPN) in 80 participants. Not yet recruiting.
31 December 2026
Quick facts
| Lead sponsor | Hannover Medical School |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 4 February 2026 |
| Primary completion | 31 December 2026 |
| Estimated completion | 28 February 2027 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Exercise Training
Conditions studied
- Myeloproliferative Neoplasms (MPN) — all drugs for Myeloproliferative Neoplasms (MPN) →
Sponsor
Hannover Medical School
Who can join
18 and older, any sex, with Myeloproliferative Neoplasms (MPN). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators will investigate the response of an individualized exercise training program on quality of life, cardiorespiratory fitness and disease-specific markers in patients with myeloproliferative neoplasms (MPN). To this end, the investigators will randomly assign patients with MPN to a training group and a waiting control group. The training group will undergo an individually tailored exercise training program for three months, while the control group will maintain their usual lifestyle for three months and then has the opportunity to undergo the three-month intervention program. At the beginning and at the end of the three-month intervention phase, the investigators will evaluate physical performance, daily physical activity, muscular strength, and self-reported outcomes and compare them between the training and the control group, in order to assess potential benefits of the exercise training program.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07384039
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Exercise Training
Trials testing the same drug.
- NCT07439224 — Qigong and Multicomponent Exercise in Panic Disorder · NA · recruiting
- NCT06627296 — The Effect of Combined Exercise and NMES on Strength, Proprioception and Reaction Time in Scapholunate Instability · NA · completed
- NCT05797857 — Exercise Training in Transthyretin Cardiac Amyloidosis · NA · recruiting
- NCT06322030 — Weight Loss and ExeRcise for Post-stroke Veterans · NA · recruiting
- NCT04909008 — Exercise Training to Improve Cardiopulmonary Hemodynamics in Heart Failure Patients · NA · suspended
Other recruiting trials for Myeloproliferative Neoplasms (MPN)
Currently open trials in the same condition.
- NCT06740916 — Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance · Phase 3 · recruiting
Other Hannover Medical School trials
Trials by the same sponsor.
- NCT06740747 — Intermittent Theta-Burst Stimulation to Improve Negative Symptoms and Cognition in Schizophrenia · NA · recruiting
- NCT06795516 — Observational Study on the Clinical Use of ex Vivo Lung Perfusion (XPS™) for Lung Transplantation · terminated
- NCT06603311 — Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of · NA · active not recruiting
- NCT06493006 — Promoting Sustainable and Active Mobility Among Employees and Students · recruiting
- NCT06042751 — Psychosomatic, Physical Activity or Both for Post-covid19 Syndrom · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07384039 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hannover Medical School
- Last refreshed: 5 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07384039.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing